Skip to content
Brad Bailey is Senior Vice President and U.S. General Manager for Genmab, a global biotechnology company at the forefront of discovering, developing, and delivering […]
Paving the way for patient-centricity in 2024 Read More »
National wastewater viral activity levels for COVID-19 have been very high since December. (It wasn’t your imagination that everyone seemed sick over the holidays.)
With the new COVID surge, are we really post-pandemic? Read More »
After the Food and Drug Administration (FDA) approved Gilead’s HIV/AIDS drug in 2001, the firm gained FDA approval for a second drug in 2015.
BIO says suit over speed of drug development is threat to innovation and new cures Read More »
The COVID pandemic brought the world to a standstill in 2020. Only within the last year or so have things started to get back
The next pandemic may be closer than we think, finds new study Read More »
Biotech has an essential role in achieving sustainable development, says a new report, Biotechnology: Driving Solutions for Sustainable Development. The report was published on
Report highlights biotech’s contributions to UN Sustainable Development Goals Read More »
The Orphan Drug Act (ODA) celebrates its birthday on January 3. The year 2024 marks 41 years of revolutionizing drug development for rare diseases
Orphan Drug Act: 40+ years of fighting rare diseases Read More »
Dengue fever has shaken health authorities around the world this year. Cases of the mosquito-borne disease have surged 30% compared to 2022, with an
Uptick in dengue cases stirs fear of new epidemiology crisis Read More »
The Inflation Reduction Act (IRA) exempts orphan drugs for rare diseases from price controls—but only if the drugs are approved for a single indication.
American biotech industry, voters support ORPHAN Cures Act Read More »
We are one step closer to pharmacy benefit manager (PBM) reform. The U.S. House approved the Lower Costs, More Transparency Act (H.R. 5378) on
House passes Lower Costs, More Transparency Act Read More »
In October 2023, Genentech announced results from the first-ever clinical trial designed exclusively to enhance the knowledge base supporting the Black and Hispanic population
Genentech Q&A: Improving MS treatment and clinical trial diversity Read More »
